Cargando…

Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy

BACKGROUND: End-stage renal disease (ESRD) is strongly associated with cardiovascular disease (CVD) risk. Advanced glycation endproducts (AGEs) and dicarbonyls, major precursors of AGEs, may contribute to the pathophysiology of CVD in ESRD. However, detailed data on the courses of AGEs and dicarbony...

Descripción completa

Detalles Bibliográficos
Autores principales: Martens, Remy J H, Broers, Natascha J H, Canaud, Bernard, Christiaans, Maarten H L, Cornelis, Tom, Gauly, Adelheid, Hermans, Marc M H, Konings, Constantijn J A M, van der Sande, Frank M, Scheijen, Jean L J M, Stifft, Frank, Kooman, Jeroen P, Schalkwijk, Casper G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577778/
https://www.ncbi.nlm.nih.gov/pubmed/33123361
http://dx.doi.org/10.1093/ckj/sfz099
_version_ 1783598245138661376
author Martens, Remy J H
Broers, Natascha J H
Canaud, Bernard
Christiaans, Maarten H L
Cornelis, Tom
Gauly, Adelheid
Hermans, Marc M H
Konings, Constantijn J A M
van der Sande, Frank M
Scheijen, Jean L J M
Stifft, Frank
Kooman, Jeroen P
Schalkwijk, Casper G
author_facet Martens, Remy J H
Broers, Natascha J H
Canaud, Bernard
Christiaans, Maarten H L
Cornelis, Tom
Gauly, Adelheid
Hermans, Marc M H
Konings, Constantijn J A M
van der Sande, Frank M
Scheijen, Jean L J M
Stifft, Frank
Kooman, Jeroen P
Schalkwijk, Casper G
author_sort Martens, Remy J H
collection PubMed
description BACKGROUND: End-stage renal disease (ESRD) is strongly associated with cardiovascular disease (CVD) risk. Advanced glycation endproducts (AGEs) and dicarbonyls, major precursors of AGEs, may contribute to the pathophysiology of CVD in ESRD. However, detailed data on the courses of AGEs and dicarbonyls during the transition of ESRD patients to renal replacement therapy are lacking. METHODS: We quantified an extensive panel of free and protein-bound serum AGEs [N(∈)-(carboxymethyl)lysine (CML), N(∈)-(carboxyethyl)lysine (CEL), N(δ)-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1)], serum dicarbonyls [glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone (3-DG)] and tissue AGE accumulation [estimated by skin autofluorescence (SAF)] in a combined cross-sectional and longitudinal observational study of patients with ESRD transitioning to dialysis or kidney transplantation (KTx), prevalent dialysis patients and healthy controls. Cross-sectional comparisons were performed with linear regression analyses, and courses following renal replacement therapy were analysed with linear mixed models. RESULTS: Free and protein-bound AGEs, dicarbonyls and SAF were higher in chronic kidney disease (CKD) Stage 5 non-dialysis (CKD 5-ND; n = 52) and CKD Stage 5 dialysis (CKD 5-D; n = 35) than in controls (n = 42). In addition, free AGEs, protein-bound CML, GO and SAF were even higher in CKD 5-D than in CKD5-ND. Similarly, following dialysis initiation (n = 43) free and protein-bound AGEs, and GO increased, whereas SAF remained similar. In contrast, following KTx (n = 21), free and protein-bound AGEs and dicarbonyls, but not SAF, markedly declined. CONCLUSIONS: AGEs and dicarbonyls accumulate in uraemia, which is even exaggerated by dialysis initiation. In contrast, KTx markedly reduces AGEs and dicarbonyls. Given their associations with CVD risk in high-risk populations, lowering AGE and dicarbonyl levels may be valuable.
format Online
Article
Text
id pubmed-7577778
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75777782020-10-28 Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy Martens, Remy J H Broers, Natascha J H Canaud, Bernard Christiaans, Maarten H L Cornelis, Tom Gauly, Adelheid Hermans, Marc M H Konings, Constantijn J A M van der Sande, Frank M Scheijen, Jean L J M Stifft, Frank Kooman, Jeroen P Schalkwijk, Casper G Clin Kidney J Original Articles BACKGROUND: End-stage renal disease (ESRD) is strongly associated with cardiovascular disease (CVD) risk. Advanced glycation endproducts (AGEs) and dicarbonyls, major precursors of AGEs, may contribute to the pathophysiology of CVD in ESRD. However, detailed data on the courses of AGEs and dicarbonyls during the transition of ESRD patients to renal replacement therapy are lacking. METHODS: We quantified an extensive panel of free and protein-bound serum AGEs [N(∈)-(carboxymethyl)lysine (CML), N(∈)-(carboxyethyl)lysine (CEL), N(δ)-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine (MG-H1)], serum dicarbonyls [glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosone (3-DG)] and tissue AGE accumulation [estimated by skin autofluorescence (SAF)] in a combined cross-sectional and longitudinal observational study of patients with ESRD transitioning to dialysis or kidney transplantation (KTx), prevalent dialysis patients and healthy controls. Cross-sectional comparisons were performed with linear regression analyses, and courses following renal replacement therapy were analysed with linear mixed models. RESULTS: Free and protein-bound AGEs, dicarbonyls and SAF were higher in chronic kidney disease (CKD) Stage 5 non-dialysis (CKD 5-ND; n = 52) and CKD Stage 5 dialysis (CKD 5-D; n = 35) than in controls (n = 42). In addition, free AGEs, protein-bound CML, GO and SAF were even higher in CKD 5-D than in CKD5-ND. Similarly, following dialysis initiation (n = 43) free and protein-bound AGEs, and GO increased, whereas SAF remained similar. In contrast, following KTx (n = 21), free and protein-bound AGEs and dicarbonyls, but not SAF, markedly declined. CONCLUSIONS: AGEs and dicarbonyls accumulate in uraemia, which is even exaggerated by dialysis initiation. In contrast, KTx markedly reduces AGEs and dicarbonyls. Given their associations with CVD risk in high-risk populations, lowering AGE and dicarbonyl levels may be valuable. Oxford University Press 2019-08-28 /pmc/articles/PMC7577778/ /pubmed/33123361 http://dx.doi.org/10.1093/ckj/sfz099 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Martens, Remy J H
Broers, Natascha J H
Canaud, Bernard
Christiaans, Maarten H L
Cornelis, Tom
Gauly, Adelheid
Hermans, Marc M H
Konings, Constantijn J A M
van der Sande, Frank M
Scheijen, Jean L J M
Stifft, Frank
Kooman, Jeroen P
Schalkwijk, Casper G
Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
title Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
title_full Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
title_fullStr Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
title_full_unstemmed Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
title_short Advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
title_sort advanced glycation endproducts and dicarbonyls in end-stage renal disease: associations with uraemia and courses following renal replacement therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577778/
https://www.ncbi.nlm.nih.gov/pubmed/33123361
http://dx.doi.org/10.1093/ckj/sfz099
work_keys_str_mv AT martensremyjh advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT broersnataschajh advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT canaudbernard advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT christiaansmaartenhl advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT cornelistom advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT gaulyadelheid advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT hermansmarcmh advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT koningsconstantijnjam advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT vandersandefrankm advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT scheijenjeanljm advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT stifftfrank advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT koomanjeroenp advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy
AT schalkwijkcasperg advancedglycationendproductsanddicarbonylsinendstagerenaldiseaseassociationswithuraemiaandcoursesfollowingrenalreplacementtherapy